Want to see CLYM full AI Analyst Report?
Climb Bio (CLYM) Stock Forecast & Price Target
740 Followers
CLYM Analyst Ratings
Strong Buy
12Buy0Hold0Sell
Based on 12 analysts giving stock ratings to Climb Bio in the past 3 months
CLYM Stock 12 Month Forecast
Average Price Target
$29.09▲(227.97% Upside)Based on 12 Wall Street analysts offering 12 month price targets for Climb Bio in the last 3 months. The average price target is $29.09 with a high forecast of $40.00 and a low forecast of $23.00. The average price target represents a 227.97% change from the last price of $8.87.
Past 12 Months12 Month ForecastJan2026Oct2026
High$40.00
Average$29.09
Low$23.00
Highest Price TargetHighest$40.00Average Price Target$29.09Lowest Price TargetLowest$23.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | Oppenheimer | $25 | buy | 181.85%Upside | Reiterated | 11/06/26 | ||
| Laura Chico | Wedbush | $25→$27 | buy | 204.40%Upside | Reiterated | 11/06/26 | ||
| Danielle Brill | Truist Financial | $25 | buy | 181.85%Upside | Reiterated | 11/06/26 | ||
| Yatin Suneja | Guggenheim | $35 | buy | 294.59%Upside | Reiterated | 11/05/26 | ||
| Julian Harrison | BTIG | $32 | buy | 260.77%Upside | Reiterated | 11/04/26 | ||
| Yasmeen Rahimi | Piper Sandler | $40 | buy | 350.96%Upside | Reiterated | 10/30/26 | ||
| Ram Selvaraju | H.C. Wainwright | $30 | buy | 238.22%Upside | Reiterated | 10/27/26 | ||
| David Hoang | Deutsche Bank | $28 | buy | 215.67%Upside | Initiated | 10/20/26 | ||
| Nevin Varghese | RBC Capital | $23 | buy | 159.30%Upside | Reiterated | 10/13/26 | ||
| Mayank Mamtani | B. Riley Securities | $26→$30 | buy | 238.22%Upside | Reiterated | 09/04/26 | ||
| Matt Phipps | William Blair | ― | buy | ― | Reiterated | 09/03/26 | ||
| Brian Skorney | Robert W. Baird | $21→$25 | buy | 181.85%Upside | Reiterated | 09/03/26 | ||
| Christopher Raymond | Raymond James | ― | buy | ― | Reiterated | 06/24/26 | ||
| Thomas Smith | Leerink Partners | ― | buy | ― | Reiterated | 06/12/26 | ||
| Geulah Livshits | Chardan Capital | $22 | buy | 148.03%Upside | Initiated | 05/05/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Unknown AnalystOppenheimerNot Ranked | BuyReiterated$25 | 11/06/26 | 181.85%Upside | ||
| Laura ChicoWedbush | BuyReiterated$25→$27 | 11/06/26 | 204.40%Upside | ||
| Danielle BrillTruist Financial | BuyReiterated$25 | 11/06/26 | 181.85%Upside | ||
| Yatin SunejaGuggenheim | BuyReiterated$35 | 11/05/26 | 294.59%Upside | ||
| Julian HarrisonBTIG | BuyReiterated$32 | 11/04/26 | 260.77%Upside | ||
| Yasmeen RahimiPiper Sandler | BuyReiterated$40 | 10/30/26 | 350.96%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiterated$30 | 10/27/26 | 238.22%Upside | ||
| David HoangDeutsche Bank | BuyInitiated$28 | 10/20/26 | 215.67%Upside | ||
| Nevin VargheseRBC Capital | BuyReiterated$23 | 10/13/26 | 159.30%Upside | ||
| Mayank MamtaniB. Riley Securities | BuyReiterated$26→$30 | 09/04/26 | 238.22%Upside | ||
| Matt PhippsWilliam Blair | BuyReiterated | 09/03/26 | ― | ||
| Brian SkorneyRobert W. Baird | BuyReiterated$21→$25 | 09/03/26 | 181.85%Upside | ||
| Christopher RaymondRaymond James | BuyReiterated | 06/24/26 | ― | ||
| Thomas SmithLeerink Partners | BuyReiterated | 06/12/26 | ― | ||
| Geulah LivshitsChardan Capital | BuyInitiated$22 | 05/05/26 | 148.03%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Climb Bio
3 Months
Success Rate5/6 ratings generated profit
83%
Average Return
+72.03%
Copying Leland Gershell's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +72.03% per trade.
1 Year
Success Rate6/8 ratings generated profit
75%
Average Return
+327.70%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +327.70% per trade.
2 Years
Success Rate7/8 ratings generated profit
88%
Average Return
+320.11%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +320.11% per trade.
CLYM Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 15 | 11 | 12 | 18 | 18 |
| Buy | 14 | 14 | 10 | 9 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 29 | 25 | 22 | 27 | 20 |
In the current month, CLYM has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLYM average Analyst price target in the past 3 months is 29.09.
CLYM Financial Forecast
High$-0.17
Consensus$-0.20
Low$-0.25
CLYM Earnings Forecast
Next quarter’s earnings estimate for CLYM is -$0.20 with a range of -$0.25 to -$0.17. The previous quarter’s EPS was -$0.18. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$0.00
Consensus$0.00
Low$0.00
CLYM Sales Forecast
Next quarter’s sales forecast for CLYM is $0 with a range of $0 to $0. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
CLYM Stock Forecast FAQ
What is CLYM’s average 12-month price target, according to analysts?
Based on analyst ratings, Climb Bio’s 12-month average price target is $29.09.
What is CLYM’s upside potential, based on the analysts’ average price target?
Climb Bio has 227.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CLYM a Buy, Sell or Hold?
Climb Bio has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Climb Bio’s price target?
The average price target for Climb Bio is $29.09. This is based on 12 12-month price targets, issued in the past 3 months. The highest analyst price target is $40.00, the lowest forecast is $23.00. The average price target represents a 227.97% increase from the current price of $8.87.
What do analysts say about Climb Bio?
Climb Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Street analysts.
How can I buy shares of CLYM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
